
Your Partner in Infectious Diseases and Vaccines
The continued increase in antibiotic resistance, emergence and re-emergence of novel infectious disease reinforces the need to develop more safe, robust, and effective anti-infective therapies and vaccines. To protect people across the globe, particularly those who have inadequate access to medical care, our team is dedicated to advancing products that help prevent and treat bacterial, viral, fungal, and parasitic infections in community-based and critical care settings.
Learn how Fortrea's infectious disease and vaccine experts bring together decades of experience from large pharma, biotech and research organizations—spanning nonclinical and clinical development of products—to efficiently support your program.
Read more on our website
Successful Phase 3 Trial for Complicated UTI
We’re excited to share an article from our collaboration with Venatorex, the sponsor of a phase three double-blind randomized clinical trial on complicated urinary tract infections, including pyelonephritis. This trial demonstrated the superiority of cefepime-taniborbactam over meropenem.
Want to dive deeper into this study? Check out the full article in the New England Journal of Medicine.
Navigating a dynamic study design in hepatitis B research
The successful execution of this platform study in hepatitis B research demonstrates the power of collaboration, expertise and adaptability in advancing complex clinical trials. At Fortrea, we are committed to supporting innovative research designs. By fostering strong relationships with sponsors and sites, embracing transparency and continuously refining our approaches, we aim to contribute to the efficient development of treatments that can make a significant difference in patients’ lives.
How Fortrea navigated complexities in a Phase I ICU trial
The landscape of ICU research, while challenging, offers immense potential for advancing critical care medicine. This Phase I trial for a novel treatment in mechanically ventilated patients illuminates several key lessons for conducting successful ICU clinical trials.
Qualified infectious disease product designation: What’s to GAIN?
The Generating Antibiotic Incentives Now (GAIN) Act was signed into US law in 2012 to enrich the drug development pipeline targeted at resistant pathogens. GAIN positions incentives and provides additional guidance to sponsors developing antibacterial and antifungal drugs intended to address serious or life-threatening infections through a regulatory designation known as Qualified Infectious Disease Product (QIDP).
Rapid diagnostic advantages in clinical research
Integrating rapid diagnostics in infectious disease clinical trials marks an important advancement in research and management. Rapid diagnostic tests (RDTs) accelerate the accurate diagnosis of infections, enabling timely and targeted interventions. Furthermore, RDTs can streamline trial processes, facilitate real-time data collection, and enhance the overall efficiency of clinical studies.

Double Dippers: The Secret Lives of Serial Study Subjects
December 16, 2024
The objective of this webinar is to discuss several measures that can help prevent multiple enrollments and enhance patient safety as part of a structured Quality by Design initiative. The experts will also share proactive operational strategies from site selection techniques to protocol design. Finally, attendees will learn how detection technologies can help identify duplicate participants, confirm eligibility and ensure the selection of high-quality subjects.
Navigating pediatric vaccine trials in LMIC


